Given that miR-17∼19b overexpression was a driver of cell death in TonB cells in a BCR-ABL-specific manner, we hypothesised that identifying key targets of the cluster could provide novel therapeutic opportunities in BCR-ABL-positive ALL. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.